▶️ Replay the Updates from the 2023 Heart Failure Conference

December 11th, 2023

December 12th, 2023

Gianluigi-Savarese

Savarese G (SE)

Frieder Braunschweig

Braunschweig F (SE)

Introduction

Marco-Metra
Marco Metra, Italy

1.1 Updates in European Guidelines on Heart failure: what changes and why?

Heart Failure Management
Ovidiu Chioncel, Germany

2.1 - Latest HFA/ESC scientific statements

Heart Failure Management
Scott D Solomon, USA

2.2- Updates from the Dapa-HF and DELIVER Programs

Giulia Ferrannini PHD Fellow MD Division of Cardiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Giulia Ferrannini, Italy

2.4 - Sodium-glucose Cotransporter 2 Inhibitors in Type 2 Diabetes

Giuseppe Rosano
Giuseppe M. C. Rosano, UK

2.6 - What to Consider When Starting a SGLT2i in a Patient with Cardiometabolic Disease

Stephan von Haehling
Stephan Von Healing, Germany

3.1 - Why to Screen HF pqtients for Iron Defiency? Epidemiology and Pathophysiology

Professor-Mark-Petrie
Mark C Petrie, UK

3.5 - GLP1-RA in Heart Failure

Giuseppe Rosano
Giuseppe Rosano, UK

4.1 - Beyond the 4 Pillars of Pharmacological Treatment in HFrEF Ivabradine

Lars Lund
Lars H. Lund, Sweden

4.2 - HFrEF beyond the 4 pillars Vericiguat

Scott Solomon
Scott Solomon, USA

4.3 - Galactic-HF: Omecamtiv Mecarbil

Javed Butler
Javed Butler, USA

5.1 - The Evolving Evidence of Potassium Binders: Latest Data on Patiromer

Giuseppe Rosano
Giuseppe Rosano, UK

5.2 - The Evolving Evidence on Potassium Binders: Latest Data on SZC

Gianluigi-Savarese
Gianluigi Savarese, Sweden

5.3 - Why do we need Potassium Binders?

Gianluigi-Savarese
Gianluigi Savarese, Sweden

6.1 - Heart Failure: Challenges in 2023

Biykem Bozkurt (USA)
Biykem Bozkurt, USA

6.2 - Strategies to Implement Use of GDMT in HF

Heart Failure Management
Ovidiu Chioncel, Germany

6.3 - Take Home Messages from the STRONG-HF Trial

Scott Solomon
Scott Solomon, USA

7-1 : PARADISE-MI: Sacubitrik/Valsartan

Stefan-James,-Sweden
Stefan James, Sweden

7-2 : Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure

Javed Butler
Javed Butler, USA

7.3 : Baseline Characteristics of the EMPACT MI Trial

Heart Failure Management
Mark Petrie, UK

7.4 - Revived

Frieder Braunschweig
Frieder Braunschweig, Sweden

8.1 - Primary Prophylactic ICD in HF: current debates

Cecilia Linde
Cecilia Linde, Sweden

8.2 - Conduction System Pacing

Javed Butler
Javed Butler, USA

9.1 - Importance to Treat MR and TR in Heart Failure

Heart Failure Congress
Marianna Adamo, Italy

9.2 - Treating MR in the context of HF effectively

Andreas-Rück,-Sweden
Andreas Ruck, Sweden

9.3 - Treating TR Today and Tomorrow

Heart Failure Congress
Marianna Adamo, Italy

10.1 - The Best of HF Publications in 2023: European Journal of Heart Failure

Biykem Bozkurt (USA)
Biykem Bozkurt, USA

10.2 - JACC: HF Strategic Initiatives 2023

Magnus-Bäck
Magnus Bäck, Sweden

10.3 - ESC Heart Failure: Journal Highlights 2023

Scroll to Top